Asia Pacific Lipid Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2023 –2030 |
 Taille du marché (année de référence) |
USD 1,843.86 Million |
 Taille du marché (année de prévision) |
USD 3,339.31 Million |
 TCAC |
% |
| Principaux acteurs du marché |
>Marché des lipides en Asie-Pacifique, par type (lipides naturels et lipides synthétiques), système lipidique (lipides neutres, lipides bactériens, lipides fluorescents, lipides bioactifs, lipides polymérisables, lipides modifiés par groupe de tête et autres), système de distribution (lipides, nanoparticules lipidiques solides , transporteurs lipidiques nanostructurés, niosomes, transférosomes et autres), source (jaune d'œuf, soja, soja non OGM, huiles purifiées, acides gras purifiés et autres), utilisateur final (industries pharmaceutiques, industries biotechnologiques, instituts universitaires et de recherche, industries cosmétiques et autres), canal de distribution (appel d'offres direct, ventes au détail et autres) - Tendances et prévisions de l'industrie jusqu'en 2030.
Analyse et perspectives du marché des lipides en Asie-Pacifique
La prévalence croissante des maladies chroniques à l'échelle mondiale a accru la demande du marché. L'augmentation des dépenses de santé pour de meilleurs services de santé contribue également à la croissance du marché. Les principaux acteurs du marché se concentrent fortement sur divers lancements de produits et approbations de médicaments au cours de cette période cruciale. En outre, la demande croissante de lipides dans diverses autres industries telles que l'industrie alimentaire et des boissons, l'industrie cosmétique et d'autres, contribue également à la demande croissante du marché des lipides.
L'augmentation des dépenses de santé et les initiatives stratégiques des acteurs du marché offrent des opportunités au marché. Cependant, les différents défis de fabrication pour la production de nanoparticules lipidiques et le manque d'établissements de santé dans les économies émergentes constituent des défis majeurs pour la croissance du marché.
Le marché des lipides de la région Asie-Pacifique devrait connaître une croissance du marché au cours de la période de prévision de 2022 à 2029. Data Bridge Market Research analyse que le marché croît avec un TCAC de 7,7 % au cours de la période de prévision de 2023 à 2030 et devrait atteindre 3 339,31 millions USD d'ici 2030 contre 1 843,86 millions USD en 2022.
|
Rapport métrique |
Détails |
|
Période de prévision |
2023 à 2030 |
|
Année de base |
2022 |
|
Années historiques |
2021 (personnalisable pour 2020-2015) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD |
|
Segments couverts |
Par type (lipides naturels et lipides synthétiques), système lipidique (lipides neutres, lipides bactériens, lipides fluorescents, lipides bioactifs, lipides polymérisables, lipides modifiés par groupe de tête et autres), système de distribution (liposomes, nanoparticules lipidiques solides , transporteurs lipidiques nanostructurés, niosomes, transférosomes et autres), source (jaune d'œuf, soja, soja non OGM, huiles purifiées, acides gras purifiés et autres), utilisateur final (industries pharmaceutiques, industries biotechnologiques, instituts universitaires et de recherche, industries cosmétiques et autres), canal de distribution (appel d'offres direct, ventes au détail et autres) |
|
Pays couverts |
Chine, Japon, Inde, Corée du Sud, Australie, Singapour, Thaïlande, Malaisie, Indonésie, Philippines, Reste de l'Asie-Pacifique |
|
Acteurs du marché couverts |
Alnylam Pharmaceutical, Inc., Croda International Plc., Moderna Inc., BioNTech SE., Pfizer Inc., Evonik Industries AG, Lipoid GmbH, Matreya LLC, VAV Life Sciences Pvt Ltd., Curia Asia-Pacific Inc., Cargill, Incorporated, Gattefossé, CD Bioparticles, Merck KGaA, NOF EUROPE GmbH, ABITEC, Cayman Chemical, CordenPharma International, CHEMI S.p.A., DSM, BASF SE, Tokyo Chemical Industry Co., Ltd., ADMSIO, Stepan Company, and Kerry |
Market Definition
Lipids can be defined as a group of organic compounds found in animals, plants, and micro- organisms. They include sterols, waxes, fats, and fat soluble vitamins. Lipids hold an ability to execute various activities. At the same time, they are known for having low toxicity levels. These qualities of lipids help in effective drug delivery. As a result, they are increasingly used as excipients in the drug production. This factor is fueling the growth of the Asia-Pacific pharmaceutical lipids market.
In recent period, the worldwide healthcare sector is going through remarkable changes. Development in drug delivery technology along with the incorporation of drug formularies is working as a driver for the growth of the pharmaceutical lipids market. Growth in quick chronic health issues and quick resulting drug delivery to the patient is one of the key factors pushing the growth of the Asia-Pacific pharmaceutical lipids market.
Lipids Market Dynamics
Drivers
-
Increase in the prevalence of chronic diseases
The encumbrance of chronic disease is briskly increasing across the globe. According to the WHO (World Health Organization), in 2021, the contribution of chronic disease was about 60%, which accounted for the number of deaths. In most Western countries, the major reason behind the increasing number of chronic diseases is the continuous increase in the aged population. The rise in the number of chronic diseases such as cardiovascular diseases, neurological disorders, and various other chronic diseases has led to an increase in the demand for various medicinal drugs that will drive the growth of the Asia-Pacific lipids market in the coming years.
-
Rising demand for lipids in food and beverage as well as the cosmetic industry
The demand for lipids in pharmaceuticals is very high as it is used in developing various drugs in the market. Also, the demand for lipids has increased in various other industries, such as in food & beverage and cosmetic products.
Lipids are an essential ingredient in the formulation of dietary supplements owing to their high content of energy and fat-soluble vitamins. Increasing health concern among people in light of COVID-19 has propelled the Asia-Pacific demand for dietary supplements. Furthermore, the availability of dietary supplements in multiple forms and flavours has made them more socially acceptable to all age groups. Growing dietary supplement consumption is expected to boost the demand for lipids over the projected years.
-
Rise in drug development
In the pharmaceutical industry, lipids and polymers are considered pillar excipients for formulating various drugs. They are used as stabilizers, solubilizes, permeation enhancers, and transfection agents. Increasing adoption of a wide range of natural, synthetic, semi-synthetic or completely artificial lipids and polymers in the formulation of various dosage forms is expected to boost the market over the forecast period.
Opportunities
-
Rise in healthcare expenditure
Healthcare expenditure has increased worldwide as people's disposable income in various countries increases. Moreover, to accomplish the population requirements, government bodies and healthcare organizations are taking the initiative to accelerate healthcare expenditure. The rise in healthcare expenditure simultaneously helps healthcare settings to improve their treatment facilities for various diseases is highly prevalent in recent years.
-
Strategic initiatives by major players
Increasing rates of various types of disease and their severity are widely seen among people globally. The dramatic rise in research quality and increasing research opportunities is because of various strategic initiatives the market players take. They are taking initiatives such as product launch, collaborations, mergers, acquisitions, and many more over the years and is expected to lead and create more opportunities in the market. Evonik invested in the short-term growth of its specialty lipids production at its Hanau and Dossenheim locations in Germany, which supplied two of the four lipids for the Pfizer/BioNTech vaccine. According to Spencer, the first batches were delivered to BioNTech in April 2021, months ahead of schedule.
Restraints/Challenges
- High cost of lipid synthesis and increasing cost of raw materials
Lipid based drugs require a huge cost for the development process. As the concept needs to be locked down, the materials need to be sourced, and it is important to consider lead times. Additionally, the process is time consuming as the drug needs sufficient time to fulfil all the clinical trials before bringing in the market for use.
Furthermore, any changes that must be re-verified will impact time. The growing advancements in biosensor assay formats and other complementary technologies demanded an effective investment for successful operations and a project risk management plan. The establishment of R&D for conducting research entails high costs, leading to expensive drugs. Thus, this factor is a major restraint for the Asia-Pacific lipids market.
- Different manufacturing challenges for lipid nanoparticle production
Lipid nanoparticles have made a major impact on the pharmaceutical industry. At their core, lipid nanoparticles (LNPs) are delivery carriers that safeguard nucleic acids. As an integral part of recent mRNA vaccines, they are injected and transported to the intended site in the cell. Despite the many advantages of lipid nanoparticles as delivery systems, the pharmaceutical industry must address significant manufacturing challenges.
These challenges include:
- Precisely controlled particle size/size distributions
- Sterilization issues
- Process repeatability and scalability
- Regulatory requirements (such as cGMP regulations)
Post COVID-19 Impact on Lipids Market
The COVID-19 has positively affected the market. As the demand for COVID-19 vaccine was on the great demand and the positive point here is the lipid is majorly used in the vaccine production. Thus COVID-19 affected lipids market positively.
Recent Developments
- In November 2022, BioNTech SE announced its Singapore affiliate BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. had entered into an agreement with Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd. to acquire one of its GMP-certified manufacturing facilities. The acquisition is part of BioNTech’s expansion strategy to strengthen its Asia-Pacific footprint in Asia.
- In September 2021, U.S. ingredients supplier ABITEC Corporation signed an amended agreement with DKSH to distribute its specialty lipids into new markets and regions across Asia-Pacific. This has helped the company to expand its business in various regions.
Asia-Pacific Lipids Market Scope
Asia-Pacific lipids market is segmented into, type, lipid systems, delivery systems, source, end user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Type
- Natural Lipid
- Synthetic Lipids
On the basis of type, the Asia-Pacific lipids market is segmented into natural lipid and synthetic lipid.
Lipid Systems
- Bioactive Lipids
- Polymerizable Lipids
- Fluorescent Lipids
- Bacterial Lipids
- Neutral Lipids
- Headgroup Modified Lipids
- Others
Based on lipid systems, the Asia-Pacific lipids market is segmented into neutral lipids, bacterial lipids, fluorescent lipids, bioactive lipids, polymerizable lipids, headgroup modified lipids and others.
Delivery Systems
- Liposomes
- Solid Lipid Nanoparticles
- Nanostructures Lipid Carrier
- Transferosomes
- Niosomes
- Others
Based on delivery systems, the Asia-Pacific lipids market is segmented into liposomes, solid lipid nanoparticles, nanostructures lipid carrier, niosomes, transferosomes and others.
Source
- Purified Fatty Acids
- Purified Oils
- Egg Yolk
- Soyabean
- Non-GMO Soyabean
- Others
Based on source, the Asia-Pacific lipids market is segmented into egg yolk, soyabean, non-GMO soyabean, purified oils, purified fatty acids and others.
End User
- Pharmaceutical Industries
- Industries de la biotechnologie
- Industrie cosmétique
- Instituts universitaires et de recherche
- Autres
En fonction de l’utilisateur final, le marché des lipides de la région Asie-Pacifique est segmenté en industries pharmaceutiques, industries biotechnologiques, instituts universitaires et de recherche, industries cosmétiques et autres.
Canal de distribution
- Appel d'offres direct
- Ventes au détail
- Autres
En fonction du canal de distribution, le marché des lipides de l'Asie-Pacifique est segmenté en appels d'offres directs, ventes au détail et autres.
Analyse/perspectives régionales du marché des lipides
Le marché des lipides est analysé et des informations sur la taille et les tendances du marché sont fournies par pays, type, systèmes lipidiques, systèmes de distribution, source, utilisateur final et canal de distribution.
Les pays couverts par le marché des lipides sont la Chine, le Japon, l’Inde, la Corée du Sud, l’Australie, Singapour, la Thaïlande, la Malaisie, l’Indonésie, les Philippines et le reste de l’Asie-Pacifique.
La Chine devrait connaître une croissance en raison du nombre croissant d'activités de recherche et de la présence de diverses sociétés pharmaceutiques et industries cosmétiques. L'augmentation des options d'utilisation et de production de lipides naturels et synthétiques stimulera le marché régional au cours de la période de prévision.
La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques, l'analyse des cinq forces de Porter et les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques d'Asie-Pacifique et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte lors de l'analyse prévisionnelle des données par pays.
Analyse du paysage concurrentiel et des parts de marché des lipides
Le paysage concurrentiel du marché des lipides fournit des détails par concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence en Asie-Pacifique, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises sur le marché des lipides.
Certains des principaux acteurs opérant sur le marché des lipides sont Alnylam Pharmaceutical, Inc., Croda International Plc., Moderna Inc., BioNTech SE., Pfizer Inc., Evonik Industries AG, Lipoid GmbH, Matreya LLC, VAV Life Sciences Pvt Ltd., Curia Asia-Pacific Inc., Cargill, Incorporated, Gattefossé, CD Bioparticles, Merck KGaA, NOF EUROPE GmbH, ABITEC, Cayman Chemical, CordenPharma International, CHEMI SpA, DSM, BASF SE, Tokyo Chemical Industry Co., Ltd., ADMSIO, Stepan Company et Kerry, entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC LIPIDS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 MERGER AND ACQUISITION, ASIA PACIFIC LIPIDS MARKET
4.4 PATENT ANALYSIS, ASIA PACIFIC LIPIDS MARKET
4.5 DRUG TREATMENT RATE BY MATURED MARKETS
4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE
4.7 KEY PRICING STRATEGIES
4.8 KEY PATIENT ENROLLMENT STRATEGIES
4.9 PRICE ANALYSIS, ASIA PACIFIC LIPIDS MARKET
4.1 ASIA PACIFIC LIPIDS MARKET, CLINICAL TRIALS
4.11 ASIA PACIFIC LIPIDS MARKET, DISTRIBUTION OF PRODUCTS BY PHASE
4.12 ASIA PACIFIC LIPIDS MARKET, PIPELINE ANALYSIS
4.13 PHASE I CANDIDATES
4.14 PHASE I/II CANDIDATES
4.15 PHASE II CANDIDATES
4.16 PHASE III CANDIDATES
5 ASIA PACIFIC LIPIDS MARKET, REGULATORY FRAMEWORK
5.1 REGULATION IN THE U.S.:
5.2 REGULATION IN EUROPE:
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASE IN THE PREVALENCE OF CHRONIC DISEASES
6.1.2 RISE IN DEMAND FOR LIPIDS IN FOOD AND BEVERAGE AS WELL AS THE COSMETIC INDUSTRY
6.1.3 INCREASE IN DRUG DEVELOPMENT
6.2 RESTRAINTS
6.2.1 HIGH COST OF LIPID SYNTHESIS AND INCREASING COST OF RAW MATERIALS
6.2.2 STRICT GOVERNMENT REGULATIONS
6.3 OPPORTUNITIES
6.3.1 RISE IN HEALTHCARE EXPENDITURE
6.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
6.4 CHALLENGES
6.4.1 DIFFERENT MANUFACTURING CHALLENGES FOR LIPID NANOPARTICLE PRODUCTION
6.4.2 LACK OF HEALTHCARE FACILITIES IN EMERGING ECONOMIES
7 ASIA PACIFIC LIPIDS MARKET, BY TYPE
7.1 OVERVIEW
7.2 NATURAL LIPID
7.2.1 UNSATURATED PHOSPHOLIPID
7.2.2 HYDROGENATED PHOSPHOLIPID
7.2.3 SPHINGOMYELIN
7.2.4 GLYCEROLPHOSPHOCHOLINE
7.3 SYNTHETIC LIPID
7.3.1 PEGYLATED PHOSPHOLIPIDS
7.3.2 PHOSPHATIDYLSERINE
7.3.3 PHOSPHATIDYGLYCEROLS
7.3.4 PHOSPHATIDYLETHANOLAMINE
7.3.5 PHOSPHATIDYLCHOLINE
7.3.6 PHOSPHATIDIC ACIDS
8 ASIA PACIFIC LIPIDS MARKET, BY LIPID SYSTEMS
8.1 OVERVIEW
8.2 BIOACTIVE LIPIDS
8.2.1 PLANT LIPIDS
8.2.2 LIPID ACTIVATORS
8.2.3 LIPID INHIBITORS
8.2.4 AGONISTS
8.2.5 BIOACTIVE CERAMIDES
8.2.6 ACYL CARNITINE LIPIDS
8.2.7 ENDOCANNABINOIDS
8.2.8 LIPO-NUCLEOTIDES
8.2.9 LYSYL-PHOSPHATIDYLGLYCEROL
8.2.10 DIACYLGLYCEROL PYROPHOSPHATE (DGPP)
8.3 POLYMERIZABLE LIPIDS
8.3.1 FUNCTIONAL PEG LIPIDS
8.3.2 MPEG STEROLS
8.3.3 MPEG CERAMIDES
8.3.4 MPEG PHOSPHOLIPIDS
8.3.5 MPEG GLYCERIDES
8.4 FLUORESCENT LIPIDS
8.4.1 FLUORESCENT SPHINGOLIPIDS
8.4.2 FLUORESCENT GLYCEROLIPIDS
8.4.3 FLUORESCENT PEG LIPIDS
8.4.4 FLUORESCENT PHOSPHOLIPIDS
8.4.5 FLUORESCENT STEROLS
8.4.6 OTHERS
8.5 BACTERIAL LIPIDS
8.5.1 MYCOLIC LIPIDS
8.5.2 N-ACYLHOMOSERINE LIPIDS
8.5.3 BRANCHED LIPIDS
8.5.4 CYCLOPROPYL LIPIDS
8.6 NEUTRAL LIPIDS
8.6.1 PRENOLS
8.6.2 VERY LONG CHAIN FATTY ACIDS
8.6.3 GLYCERIDES
8.6.4 EICSANOIDS
8.6.5 OXYGENATED FATTY ACIDS
8.6.6 GLYCOSYLATED DIACYL GLYCEROLS
8.6.7 PROSTAGLANDINS
8.7 HEADGROUP MODIFIED LIPIDS
8.7.1 FUNCTIONAL LIPIDS
8.7.2 ANTIGENIC LIPIDS
8.7.3 GLYCOSYLATED LIPIDS
8.7.4 CHELATORS
8.7.5 ADHESIVE LIPIDS
8.7.6 SNAP-TAG REACTING LIPIDS
8.7.7 ALKYL PHOSPHATES
8.8 OTHERS
9 ASIA PACIFIC LIPIDS MARKET, BY DELIVERY SYSTEMS
9.1 OVERVIEW
9.2 LIPOSOMES
9.2.1 LIPOSOMES FOR DNA/RNA
9.2.1.1 DOTAP LIPOSOMES FOR DNA/RNA DELIVERY
9.2.1.2 DDAB LIPOSOMES FOR DNA/RNA DELIVERY
9.2.1.3 GL-67 LIPOSOMES FOR DNA/RNA DELIVERY
9.2.1.4 DC-CHOLESTEROL LIPOSOMES FOR DNA/RNA DELIVERY
9.2.1.5 DOTMA LIPOSOMES FOR DNA/RNA DELIVERY
9.2.1.6 DODAP LIPOSOMES FOR DNA/RNA DELIVERY
9.2.2 REACTIVE LIPOSOMES
9.2.2.1 SUCCINYL LIPOSOMES
9.2.2.2 DBCO LIPOSOMES
9.2.2.3 BIOTINYLATED LIPOSOMES
9.2.2.4 CARBOXYLIC ACID LIPOSOMES
9.2.2.5 AMINE LIPOSOMES
9.2.2.6 CYANUR LIPOSOMES
9.2.2.7 AZIDE LIPOSOMES
9.2.2.8 FOLATE LIPOSOMES
9.2.2.9 DODECANYL LIPOSOMES
9.2.2.10 NI REACTIVE LIPOSOMES
9.2.2.11 PDP LIPOSOMES
9.2.2.12 GLUTARYL LIPOSOMES
9.2.2.13 OTHERS
9.2.3 DRUG LOADED LIPOSOMES
9.2.4 PLAIN LIPOSOMES
9.2.4.1 CARDIOLIPIN LIPIDS LIPOSOMES
9.2.4.2 DOTAP LIPOSOMES
9.2.4.3 PHOSPHATIDYLSERINE LIPOSOMES
9.2.4.4 PHOSPHATIDYLCHOLINE LIPOSOMES
9.2.4.5 PHOSPHATIDYL GLYCEROL LIPOSOMES
9.2.4.6 OTHERS
9.3 SOLID LIPID NANOPARTICLES
9.4 NANOSTRUCTURES LIPID CARRIER
9.5 TRANSFEROSOMES
9.6 NIOSOMES
9.7 OTHERS
10 ASIA PACIFIC LIPIDS MARKET, BY SOURCE
10.1 OVERVIEW
10.2 PURIFIED FATTY ACIDS
10.3 PURIFIED OILS
10.4 EGG YOLK
10.5 SOYABEAN
10.6 NON-GMO SOYABEAN
10.7 OTHERS
11 ASIA PACIFIC LIPIDS MARKET, BY END USER
11.1 OVERVIEW
11.2 PHARMACEUTICAL INDUSTRIES
11.3 BIOTECHNOLOGY INDUSTRIES
11.4 COSMETIC INDUSTRIES
11.5 ACADEMIC AND RESEARCH INSTITUTES
11.6 OTHERS
12 ASIA PACIFIC LIPIDS MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
12.4 OTHERS
13 ASIA PACIFIC LIPIDS MARKET, BY REGION
13.1 ASIA-PACIFIC
13.1.1 CHINA
13.1.2 JAPAN
13.1.3 SOUTH KOREA
13.1.4 INDIA
13.1.5 AUSTRALIA
13.1.6 SINGAPORE
13.1.7 THAILAND
13.1.8 MALAYSIA
13.1.9 INDONESIA
13.1.10 PHILIPPINES
13.1.11 REST OF ASIA PACIFIC
14 ASIA PACIFIC LIPIDS MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 BIONTECH SE.
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENT
16.2 MODERNA, INC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 PFIZER INC.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 CARGILL, INCORPORATED.
16.4.1 COMPANY SNAPSHOT
16.4.2 COMPANY SHARE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENTS
16.5 KERRY.
16.5.1 COMPANY SNAPSHOT
16.5.2 COMPANY SHARE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENTS
16.6 ABITEC
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENTS
16.7 ADMSIO
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENTS
16.8 ALNYLAM PHARMACEUTICALS, INC.
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENT
16.9 BASF SE
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENTS
16.1 CAYMAN CHEMICAL
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENTS
16.11 CD BIOPARTCLES.
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENTS
16.12 CHEMI S.P.A.
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENTS
16.13 CORDENPHARMA INTERNATIONAL
16.13.1 COMPANY SNAPSHOT
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENTS
16.14 CRODA INTERNATIONAL PLC.
16.14.1 COMPANY SNAPSHOT
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENTS
16.15 CURIA ASIA PACIFIC, INC.
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT
16.16 DSM
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENTS
16.17 EVONIK INDUSTRIES AG
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENTS
16.18 GATTEFOSSÉ
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENTS
16.19 LIPOID GMBH
16.19.1 COMPANY SNAPSHOT
16.19.2 PRODUCT PORTFOLIO
16.19.3 RECENT DEVELOPMENT
16.2 MATREYA, LLC
16.20.1 COMPANY SNAPSHOT
16.20.2 PRODUCT PORTFOLIO
16.20.3 RECENT DEVELOPMENTS
16.21 MERCK KGAA
16.21.1 COMPANY SNAPSHOT
16.21.2 PRODUCT PORTFOLIO
16.21.3 RECENT DEVELOPMENTS
16.22 NOF EUROPE GMBH
16.22.1 COMPANY SNAPSHOT
16.22.2 PRODUCT PORTFOLIO
16.22.3 RECENT DEVELOPMENTS
16.23 STEPAN COMPANY
16.23.1 COMPANY SNAPSHOT
16.23.2 PRODUCT PORTFOLIO
16.23.3 RECENT DEVELOPMENTS
16.24 TOKYO CHEMICAL INDUSTRY CO., LTD.
16.24.1 COMPANY SNAPSHOT
16.24.2 PRODUCT PORTFOLIO
16.24.3 RECENT DEVELOPMENTS
16.25 VAV LIFE SCIENCES PVT LTD
16.25.1 COMPANY SNAPSHOT
16.25.2 PRODUCT PORTFOLIO
16.25.3 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
Liste des tableaux
TABLE 1 ASP FOR MAJOR DRUGS IN LIPIDS MARKET (PRICE IN USD)
TABLE 2 LIPID BASED NANO PARTICLE FOR COVID-19 VACCINES
TABLE 3 LIPID BASED NANO PARTICLE FOR CANCER VACCINES
TABLE 4 RNA ENCAPSULATED LIPID NANOPARTICLES
TABLE 5 LIPOSOMAL FORMULATIONS
TABLE 6 LIPID BASED NANO PARTICLE FOR COVID VACCINES
TABLE 7 LIPOSOMAL FORMULATION
TABLE 8 LIPID BASED NANO PARTICLE FOR CANCER VACCINES
TABLE 9 RNA ENCAPSULATED LIPID NANOPARTICLES
TABLE 10 LIPOSOME FORMULATIONS
TABLE 11 LIPID BASED NANO PARTICLE FOR COVID VACCINES
TABLE 12 LIPID BASED NANO PARTICLE FOR CANCER VACCINES
TABLE 13 LIPOSOMAL FORMULATION
TABLE 14 ASIA PACIFIC LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 15 ASIA PACIFIC NATURAL LIPID IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 ASIA PACIFIC NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 17 ASIA PACIFIC SYNTHETIC LIPID IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 ASIA PACIFIC SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 19 ASIA PACIFIC LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 20 ASIA PACIFIC BIOACTIVE LIPIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 ASIA PACIFIC BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 22 ASIA PACIFIC POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 ASIA PACIFIC POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 24 ASIA PACIFIC FLUORESCENT LIPIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 ASIA PACIFIC FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 26 ASIA PACIFIC BACTERIAL LIPIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 ASIA PACIFIC BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 28 ASIA PACIFIC NEUTRAL LIPIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 ASIA PACIFIC NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 30 ASIA PACIFIC HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 ASIA PACIFIC HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 32 ASIA PACIFIC OTHERS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 ASIA PACIFIC LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 34 ASIA PACIFIC LIPOSOMES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 ASIA PACIFIC LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 36 ASIA PACIFIC LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 37 ASIA PACIFIC REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 38 ASIA PACIFIC PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 39 ASIA PACIFIC SOLID LIPID NANOPARTICLES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 ASIA PACIFIC NANOSTRUCTURES LIPID CARRIER IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 ASIA PACIFIC TRANSFEROSOMES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 ASIA PACIFIC NIOSOMES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 ASIA PACIFIC OTHERS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 ASIA PACIFIC LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 45 ASIA PACIFIC PURIFIED FATTY ACIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 ASIA PACIFIC PURIFIED OILS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 ASIA PACIFIC EGG YOLK IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 ASIA PACIFIC SOYABEAN IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 49 ASIA PACIFIC NON-GMO SOYABEAN IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 ASIA PACIFIC OTHERS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 51 ASIA PACIFIC LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 52 ASIA PACIFIC PHARMACEUTICAL INDUSTRIES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 ASIA PACIFIC BIOTECHNOLOGY INDUSTRIES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 54 ASIA PACIFIC COSMETIC INDUSTRIES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 55 ASIA PACIFIC ACADEMIC AND RESEARCH INSTITUTES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 56 ASIA PACIFIC OTHERS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 ASIA PACIFIC LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 58 ASIA PACIFIC DIRECT TENDER IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 59 ASIA PACIFIC RETAIL SALES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 60 ASIA PACIFIC OTHERS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 61 ASIA-PACIFIC LIPIDS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 62 ASIA-PACIFIC LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 63 ASIA-PACIFIC NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 64 ASIA-PACIFIC SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 65 ASIA-PACIFIC LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 66 ASIA-PACIFIC NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 67 ASIA-PACIFIC BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 68 ASIA-PACIFIC FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 69 ASIA-PACIFIC BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 70 ASIA-PACIFIC POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 71 ASIA-PACIFIC HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 72 ASIA-PACIFIC LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 73 ASIA-PACIFIC LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 74 ASIA-PACIFIC LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 75 ASIA-PACIFIC REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 76 ASIA-PACIFIC PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 77 ASIA-PACIFIC LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 78 ASIA-PACIFIC LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 79 ASIA-PACIFIC LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 80 CHINA LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 81 CHINA NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 82 CHINA SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 83 CHINA LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 84 CHINA NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 85 CHINA BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 86 CHINA FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 87 CHINA BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 88 CHINA POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 89 CHINA HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 90 CHINA LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 91 CHINA LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 92 CHINA LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 93 CHINA REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 94 CHINA PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 95 CHINA LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 96 CHINA LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 97 CHINA LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 98 JAPAN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 99 JAPAN NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 100 JAPAN SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 101 JAPAN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 102 JAPAN NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 103 JAPAN BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 104 JAPAN FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 105 JAPAN BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 106 JAPAN POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 107 JAPAN HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 108 JAPAN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 109 JAPAN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 110 JAPAN LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 111 JAPAN REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 112 JAPAN PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 113 JAPAN LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 114 JAPAN LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 115 JAPAN LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 116 SOUTH KOREA LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 117 SOUTH KOREA NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 118 SOUTH KOREA SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 119 SOUTH KOREA LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 120 SOUTH KOREA NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 121 SOUTH KOREA BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 122 SOUTH KOREA FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 123 SOUTH KOREA BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 124 SOUTH KOREA POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 125 SOUTH KOREA HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 126 SOUTH KOREA LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 127 SOUTH KOREA LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 128 SOUTH KOREA LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 129 SOUTH KOREA REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 130 SOUTH KOREA PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 131 SOUTH KOREA LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 132 SOUTH KOREA LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 133 SOUTH KOREA LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 134 INDIA LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 135 INDIA NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 136 INDIA SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 137 INDIA LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 138 INDIA NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 139 INDIA BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 140 INDIA FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 141 INDIA BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 142 INDIA POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 143 INDIA HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 144 INDIA LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 145 INDIA LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 146 INDIA LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 147 INDIA REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 148 INDIA PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 149 INDIA LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 150 INDIA LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 151 INDIA LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 152 AUSTRALIA LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 153 AUSTRALIA NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 154 AUSTRALIA SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 155 AUSTRALIA LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 156 AUSTRALIA NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 157 AUSTRALIA BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 158 AUSTRALIA FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 159 AUSTRALIA BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 160 AUSTRALIA POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 161 AUSTRALIA HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 162 AUSTRALIA LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 163 AUSTRALIA LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 164 AUSTRALIA LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 165 AUSTRALIA REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 166 AUSTRALIA PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 167 AUSTRALIA LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 168 AUSTRALIA LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 169 AUSTRALIA LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 170 SINGAPORE LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 171 SINGAPORE NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 172 SINGAPORE SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 173 SINGAPORE LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 174 SINGAPORE NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 175 SINGAPORE BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 176 SINGAPORE FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 177 SINGAPORE BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 178 SINGAPORE POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 179 SINGAPORE HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 180 SINGAPORE LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 181 SINGAPORE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 182 SINGAPORE LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 183 SINGAPORE REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 184 SINGAPORE PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 185 SINGAPORE LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 186 SINGAPORE LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 187 SINGAPORE LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 188 THAILAND LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 189 THAILAND NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 190 THAILAND SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 191 THAILAND LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 192 THAILAND NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 193 THAILAND BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 194 THAILAND FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 195 THAILAND BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 196 THAILAND POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 197 THAILAND HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 198 THAILAND LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 199 THAILAND LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 200 THAILAND LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 201 THAILAND REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 202 THAILAND PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 203 THAILAND LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 204 THAILAND LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 205 THAILAND LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 206 MALAYSIA LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 207 MALAYSIA NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 208 MALAYSIA SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 209 MALAYSIA LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 210 MALAYSIA NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 211 MALAYSIA BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 212 MALAYSIA FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 213 MALAYSIA BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 214 MALAYSIA POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 215 MALAYSIA HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 216 MALAYSIA LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 217 MALAYSIA LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 218 MALAYSIA LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 219 MALAYSIA REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 220 MALAYSIA PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 221 MALAYSIA LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 222 MALAYSIA LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 223 MALAYSIA LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 224 INDONESIA LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 225 INDONESIA NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 226 INDONESIA SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 227 INDONESIA LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 228 INDONESIA NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 229 INDONESIA BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 230 INDONESIA FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 231 INDONESIA BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 232 INDONESIA POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 233 INDONESIA HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 234 INDONESIA LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 235 INDONESIA LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 236 INDONESIA LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 237 INDONESIA REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 238 INDONESIA PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 239 INDONESIA LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 240 INDONESIA LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 241 INDONESIA LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 242 PHILIPPINES NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 243 PHILIPPINES NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 244 PHILIPPINES SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 245 PHILIPPINES LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 246 PHILIPPINES NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 247 PHILIPPINES BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 248 PHILIPPINES FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 249 PHILIPPINES BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 250 PHILIPPINES POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 251 PHILIPPINES HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 252 PHILIPPINES LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 253 PHILIPPINES LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 254 PHILIPPINES LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 255 PHILIPPINES REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 256 PHILIPPINES PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 257 PHILIPPINES LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 258 PHILIPPINES LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 259 PHILIPPINES LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 260 REST OF ASIA-PACIFIC LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
Liste des figures
FIGURE 1 ASIA PACIFIC LIPIDS MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC LIPIDS MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC LIPIDS MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC LIPIDS MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC LIPIDS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC LIPIDS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC LIPIDS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA PACIFIC LIPIDS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 ASIA PACIFIC LIPIDS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC LIPIDS MARKET: SEGMENTATION
FIGURE 11 THE GROWING PRVALENCE OF CHRONIC DISEASES AND RISING DEMAND FOR LIPIDS IN VARIOUS INDUSTRIES ARE EXPECTED TO DRIVE THE ASIA PACIFIC LIPIDS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 12 TESTING SERVICES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC LIPIDS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC LIPIDS MARKET
FIGURE 14 ASIA PACIFIC LIPIDS MARKET: BY TYPE, 2022
FIGURE 15 ASIA PACIFIC LIPIDS MARKET: BY TYPE, 2023-2030 (USD MILLION)
FIGURE 16 ASIA PACIFIC LIPIDS MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 17 ASIA PACIFIC LIPIDS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 18 ASIA PACIFIC LIPIDS MARKET: BY LIPID SYSTEMS, 2022
FIGURE 19 ASIA PACIFIC LIPIDS MARKET: BY LIPID SYSTEMS, 2023-2030 (USD MILLION)
FIGURE 20 ASIA PACIFIC LIPIDS MARKET: BY LIPID SYSTEMS, CAGR (2023-2030)
FIGURE 21 ASIA PACIFIC LIPIDS MARKET: BY LIPID SYSTEMS, LIFELINE CURVE
FIGURE 22 ASIA PACIFIC LIPIDS MARKET: BY DELIVERY SYSTEMS, 2022
FIGURE 23 ASIA PACIFIC LIPIDS MARKET: BY DELIVERY SYSTEMS, 2023-2030 (USD MILLION)
FIGURE 24 ASIA PACIFIC LIPIDS MARKET: BY DELIVERY SYSTEMS, CAGR (2023-2030)
FIGURE 25 ASIA PACIFIC LIPIDS MARKET: BY DELIVERY SYSTEMS, LIFELINE CURVE
FIGURE 26 ASIA PACIFIC LIPIDS MARKET: BY SOURCE, 2022
FIGURE 27 ASIA PACIFIC LIPIDS MARKET: BY SOURCE, 2023-2030 (USD MILLION)
FIGURE 28 ASIA PACIFIC LIPIDS MARKET: BY SOURCE, CAGR (2023-2030)
FIGURE 29 ASIA PACIFIC LIPIDS MARKET: BY SOURCE, LIFELINE CURVE
FIGURE 30 ASIA PACIFIC LIPIDS MARKET: BY END USER, 2022
FIGURE 31 ASIA PACIFIC LIPIDS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 32 ASIA PACIFIC LIPIDS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 33 ASIA PACIFIC LIPIDS MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 ASIA PACIFIC LIPIDS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 35 ASIA PACIFIC LIPIDS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 36 ASIA PACIFIC LIPIDS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 37 ASIA PACIFIC LIPIDS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 ASIA-PACIFIC LIPIDS MARKET: SNAPSHOT (2022)
FIGURE 39 ASIA-PACIFIC LIPIDS MARKET: BY COUNTRY (2022)
FIGURE 40 ASIA-PACIFIC LIPIDS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 41 ASIA-PACIFIC LIPIDS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 42 ASIA-PACIFIC LIPIDS MARKET: BY TYPE (2023 & 2030)
FIGURE 43 ASIA PACIFIC LIPIDS MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
